Oct4A is a core component of the regulatory network of pluripotent cells, and by itself can reprogram neural stem cells into pluripotent cells in mice and humans. However, its role in defining totipotency and inducing pluripotency during embryonic development is still unclear. We genetically eliminated maternal Oct4A using a Cre/loxP approach in mouse and found that the establishment of totipotency was not affected, as shown by the generation of live pups. After complete inactivation of both maternal and zygotic Oct4A expression, the embryos still formed Oct4-GFP-and Nanog-expressing inner cell masses, albeit non-pluripotent, indicating that Oct4A is not a determinant for the pluripotent cell lineage separation. Interestingly, Oct4A-deficient oocytes were able to reprogram fibroblasts into pluripotent cells. Our results clearly demonstrate that, in contrast to its role in the maintenance of pluripotency, maternal Oct4A is not crucial for either the establishment of totipotency in embryos, or the induction of pluripotency in somatic cells using oocytes.
through a positive autoregulatory loop in ESCs 5 . Interestingly, Oct4 is listed as one of the 27 proven maternal-effect genes, and is regarded as being functionally important for zygotic genome activation 6 , which provides the first step in the establishment of totipotency-pluripotency. Functionally, Oct4 is required for the binding of two key components of the BMP (bone morphogenetic protein) and LIF (leukaemia inhibitory factor) signalling pathways, Smad1 and STAT3, to their respective targets, and plays a pivotal role in stabilizing the transcription factor complex 7 . Among the core components of the pluripotency circuitry formed by Oct4, Nanog and Sox2, Nanog is directly regulated by Oct4 and Sox2 (ref. 8) , Sox2 is actually dispensable for the activation of Oct/Sox enhancers, and the forced expression of Oct4 could rescue Sox2-null ESCs 9 . Hence, Oct4 is considered to be the genetic 'master switch' in the establishment of totipotency-pluripotency during the life cycle of mammals 10 , and is presumed to be the most upstream gene in the molecular circuitry of pluripotency 11 . Here, however, we provide solid evidence that challenges this viewpoint.
We used Oct4-floxed mice, in which two loxP motifs had been inserted that span the proximal promoter and the Oct4A unique first exon 12 ( Supplementary Fig. S1a ). As the other four exons shared by Oct4B were not mutated, the Oct4 studied is hereafter referred to as Oct4A. Conditional removal of maternal Oct4A from oocytes was done by crossing the Oct4 flox/flox mice with Zp3Cre transgenic mice as shown in Supplementary Fig. S1b . Genotyping for Oct4A deletion in single germinal vesicle oocytes (47/47) ( Fig. 1a ), mature metaphase II oocytes (28/28), preimplantation embryos (665/666) and offspring (95/97) confirmed the efficient deletion of the floxed Oct4A allele by Zp3Cre. Depletion of the maternal Oct4A messenger RNA was also demonstrated, without a significant reduction in the expression of the oocyte-specific genes Sall4, Stella and Dazl by real-time PCR with reverse transcription (RT-PCR) with TaqMan probe/primer sets, using both the ABI PRISM 7900 sequence detection system ( Fig. 1b ) and the Fluidigm Biomark 48.48 dynamic array system ( Supplementary Fig. S1e Supplementary Fig. S5 , and source data for b,e are shown in Suplementary  Table S5 . the maternal Oct4A protein was confirmed by western blot on pools of more than 400 oocytes per sample ( Supplementary Fig. S1d ). However, using the TaqMan Oct4 primers spanning exon 2 and exon 3, real-time RT-PCR data consistently showed 1-3% of the wild-type (WT) expression level in the Oct4A-null oocytes and embryos ( Fig. 2a ). Such a low level of Oct4 expression has also been observed previously in samples with genetically inactive Oct4 loci using the same Oct4-floxed mice, and was considered to be the background noise of detection methods, the expression of pseudogenes or the expression of other POU-domain family members 13 . However, no detectable background signal was found in our Oct4A-null samples using Oct4A-specific primers spanning exons 1 and 2 ( Fig. 2b) . To identify the background signal, we sequenced the amplicons obtained with the TaqMan primer set ( Fig. 2c,d ), along with another primer set spanning exons 3 and 4 ( Fig. 2e,f ). As shown in Supplementary Tables S1 and S2, both primer sets amplified sequences matching the Oct4 mRNA. These results suggested that low levels of Oct4B were expressed in the Oct4A-null oocytes and embryos. Regardless, even though the exact function of Oct4B in mouse oocytes and embryos remains unknown, numerous studies have demonstrated that the Oct4B exists in somatic cells 14, 15 , acts as a stress response factor 16 , or an antiapoptotic factor in cancer cells 17 , and only Oct4A has the ability to confer and sustain pluripotency 15 . Combined with Sox2, Klf4 and c-Myc, Oct4B was not able to reprogram somatic cells into induced pluripotent stem cells, unlike Oct4A (ref. 15 ). Our data showed that the low level of Oct4B expression in Oct4A-null embryos could not maintain pluripotency in vitro or in vivo. Therefore, we consider it highly unlikely that the low levels of Oct4B expression in oocytes, embryos and ESCs can compensate for the critical roles of Oct4A in the establishment of totipotency and pluripotency.
Previous reports have speculated that maternal Oct4 is a key regulator of oocyte developmental competence, on the basis of microarray gene profiling on metaphase II oocytes with minor germinal vesicle morphological variation 18 . Oct4 was also claimed to be a critical regulator of the maternal-embryonic transition, as embryos arrested in development after being invasively injected with Oct4-antisense morpholino oligonucleotides at the zygote stage without validation of efficiency and specificity, whereas the existing maternal Oct4 protein was ignored 19 . Here we investigated the functionality of Oct4A-null oocytes in vivo by crossing Oct4 flox/flox -Zp3 Cre/+ female mice with WT male mice. To our surprise, we found that these Oct4 flox/flox -Zp3 Cre/+ female mice were fully fertile, with a normal litter size averaging 7.9 pups ( Supplementary Fig. S1f ); all these offspring had deletion of the maternal Oct4A allele, as confirmed by PCR genotyping ( Supplementary Fig. S1g ), demonstrating that maternal Oct4A is not critical for totipotency-pluripotency.
Next, we analysed gene expression using immunocytochemistry and real-time RT-PCR in Oct4A-null blastocysts obtained by crossing Oct4 flox/flox -Zp3 Cre/+ female mice with Oct4A +/ male mice. In total, we obtained 264 maternal-and zygotic-knockout embryos and 302 maternal-knockout and zygotic-WT embryos. As maternal-knockout and zygotic-WT embryos underwent normal full-term development and had the same genetic background, they were used as control for maternal-and zygotic-knockout embryos. Although the maternal-and zygotic-knockout blastocysts had a reduced size on embryonic day E4.5 (102.4 ± 19.6 µm in diameter, n = 33, versus control 124.7 ± 24.4 µm, n = 60; P < 0.01), they exhibited normal cavitation and formed a distinct ICM (Supplementary Video S1). Notably, on E3.5, the ICM of maternal/zygotic-knockout embryos did not express the trophectoderm markers Cdx2 (Figs 1c and 3a) and Troma-1 ( Supplementary  Fig. S2d ). Instead, they expressed Nanog, another core factor involved in the regulatory network of ESC self-renewal and pluripotency 20 , at protein (Figs 1d and 3a) and mRNA levels ( Fig. 1e ) comparable to those of the zygotic mutant, although the Nanog + cells were always found to scatter apart in the ICM (Figs 1d and 3b ). Activation of Nanog expression was observed as early as at the eight-cell stage at mRNA ( Supplementary Fig. S2b ) and protein levels ( Supplementary Fig. S2c ), as in control embryos. On E4.5, although the ICM of maternal-and zygotic-knockout embryos maintained Nanog expression in 35 of the 41 blastocysts examined, co-expression of Cdx2 in some of the Nanog + ICM cells ( Fig. 3b and Supplementary Fig. S2e ) was observed in 73.1% (30/41) of the knockout embryos, whereas such co-localization was rarely seen in control littermate embryos (3.3%, 2/61). Moreover, we examined the expression of the Oct4-GFP transgene in maternal-and zygotic-knockout embryos by crossing Oct4 flox/flox -Zp3 Cre/+ female mice with Oct4 +/ -GOF18 +/+ male mice. Green fluorescent protein (GFP) of the Oct4-GFP transgene in GOF18 mice is expressed under the control of Oct4 regulatory elements and is active only in pluripotent cells and cells of the germ cell lineage 21 , and as such it has been used as a convenient indicator for the acquisition of pluripotency. The time-lapse observation revealed that Oct4-GFP expression was activated in all maternal-knockout embryos (nos 2, 6, 7 and 10-14) and maternal-and zygotic-knockout embryos (nos 5 and 9) in a timely fashion, as in WT embryos (nos 1, 3, 4 and 8 in Fig. 3c and Supplementary Video S2). The genotype of each individual embryo was determined by nested PCR ( Supplementary Fig. S3c ) at the end of time-lapse observation, with its position tracked in the video with bright-field microscopy (Supplementary Fig. S3a and Video S3). This result is consistent with a report showing the maintenance of β-galactosidase activity from the Oct4 promoter in the ICM of zygotic Oct4-knockout embryos 4 . Whereas expression of Nanog and Oct4-GFP is persistent, expression of Cdx2 in Oct4-null E4.5 embryos was upregulated at the mRNA level, as assessed by real-time RT-PCR analysis on immunosurgically prepared ICMs ( Fig. 3d ), indicating a reciprocal interaction between Oct4 and Cdx2 at this stage.
Previous studies have suggested that lineage commitment is controlled by the expression level of Oct4 (refs 4,22) . Repression of Oct4 expression was shown to induce the differentiation of ESCs into trophectoderm, and a less than twofold increase in Oct4 expression was shown to cause differentiation of ESCs into cells of primitive endoderm and mesoderm 22 . In the absence of Oct4, embryos could not form an ICM-that is, the inner cells of morula-stage embryos were rather driven into trophoblast differentiation 4 . Therefore, these results indicated that Oct4 plays a critical role in sustaining stem cell self-renewal and that up-or downregulation of Oct4 induces divergent developmental programs, suggesting that Oct4 is the master regulator of pluripotency and that it may also control lineage commitment during early embryonic development 4 . This hypothesis was further strengthened by the finding of the reciprocal interaction between Oct4 and Cdx2 in determining trophectoderm differentiation 23 and by the interaction between Oct4 and the histone H3-specific methyltransferase ESET in restricting the extraembryonic trophoblast lineage potential of pluripotent cells 24 . However, co-expression of Oct4 and Cdx2 was found in normal morula-stage embryos 25 , and expression of Cdx2 in ESCs was found to be rapidly initiated by Ras activation (that is, within 24 h), without previous or simultaneous downregulation of Oct4 expression 26 . Moreover, Cdx2 deficiency was not shown to interrupt trophectoderm-ICM lineage separation [27] [28] [29] . Meanwhile, zygotic Oct4 expression was shown not to be required for initial repression of the trophectoderm genes Cdx2 and Gata3, indicating that other mechanisms must lead to the restriction of these genes to the trophectoderm (ref. 30 ). Now with our maternal Oct4A-knockout results, we added more solid evidence against the Oct4-Cdx2 interaction model of lineage commitment in early mouse embryos 23 . Our results clearly demonstrated that ICM-trophectoderm lineages were separated in maternal and zygotic Oct4A-knockout embryos, suggesting that first lineage separation of Supplementary Table S5 .
the ICM-trophectoderm is not determined by the reciprocal interaction between Oct4 and Cdx2. Instead, such a reciprocal interaction between Oct4 and Cdx2 is established subsequently to maintain the ICM fate. Most importantly, we found that maternal Oct4A is not at the root of pluripotency as a determinant in initiating the pluripotent cell lineage, contrary to previous assumptions and views. Notably, in contrast to ESCs, wherein upstream Oct4 and Sox2 regulate Nanog expression 8, 31 , we found that activation of Nanog and Oct4-GFP expression occurred in the absence of both maternal and zygotic Oct4A, further suggesting that a unique Oct4A-independent pluripotency-initiating regulatory network is active in early embryos.
By crossing Oct4 flox/flox -Zp3 Cre/+ female mice with Oct4 +/ -OG2 +/− male mice, in which the Oct4-GFP transgene lacks the proximal enhancer and activates GFP expression through the distal enhancer and promoter (GOF18 PE; ref. 32) , we demonstrated that GFP is still activated in Oct4A-null embryos ( Supplementary Fig. S3b ). This result indicates that, in oocytes and embryos, such an unknown Oct4independent reprogramming engine activates Oct4 expression through the distal enhancer, probably through a completely different network than that shown by Yamanaka's four-factor reprogramming [33] [34] [35] .
In an attempt to identify the factors critical for driving Oct4 and Nanog expression, we knocked down six reported Oct4-regulating factors, Sall4, Tpt1, Zscan4, Esrrb, Utf1 and Nr5a2, by microinjecting gene-specific short interfering RNA (siRNA) duplexes into maternal Oct4A-deficient zygotes, to avoid any possible effect of maternal Oct4A as a positive autoregulator. The efficient knockdown of Sall4, Tpt1, Zscan4, Esrrb and Utf1 was observed at the blastocyst stage. However, we did not observe any significant change in either Oct4 expression ( Fig. 3e and Supplementary Fig. S3e ) or Oct4-GFP activation ( Supplementary  Fig. S3d ). Interestingly, knockdown of Nr5a2 showed a mild, but consistent, downregulation of Oct4 expression (P < 0.0001; Fig. 3f ). Nr5a2, an orphan nuclear receptor, was found to maintain Oct4 expression at the epiblast stage of embryonic development, by binding to the proximal enhancer and proximal promoter regions of Oct4, but to play no evident role in ESC self-renewal 36 . However, Nr5a2 can induce epiblast stem cells into ground state pluripotency 37 and replace Oct4 in the reprogramming of somatic cells into pluripotent cells 34 . Our results indicate the involvement of Nr5a2 in vivo in assisting Oct4 activation in preimplantation embryos. Further studies to elucidate how exactly oocytes activate the pluripotent genes Oct4A and Nanog on top of the Oct4-Sox2 autoregulatory loop will lead to a better understanding of the establishment of totipotency in zygotes and in transplanted somatic cells, and to a marked improvement in the efficiency of induced pluripotent stem cell techniques, and eventually support the generation of Oct4-independent induced totipotent stem cells to achieve organized differentiation into an intact organism without the use of oocytes through fertilization or nuclear transfer (NT).
On the other hand, we found low levels of Tbx1 expression in WT E3.5 blastocysts ( Fig. 1e ) and E4.5 ICM (Fig. 3d ) by real-time RT-PCR with a threshold cycle (C T ) value of 33 and 28-31, respectively, but we could not detect Tbx1 mRNA in any Oct4A-null samples even after 40 cycles of PCR amplification. Tbx1 encodes a T-box transcription factor and is expressed in different components of the mesoderm or mesoderm-endoderm during gastrulation 38 . Mutation of TBX1 causes the DiGeorge syndrome phenotype, which manifests as defects in the pharyngeal arch and in cardiovascular and craniofacial development 39 .
Chromatin immunoprecipitation sequencing data have shown that Oct4 binds to the promoter region of Tbx1 (ref. 7) . Further study of how Oct4A activates Tbx1 expression might reveal another role of Oct4A in the initiation of mesoderm differentiation by promoting pluripotent cells in a 'poised' state.
Next, we evaluated the pluripotency of maternal-zygotic Oct4Aknockout embryos in vitro by plating them onto mouse embryonic fibroblasts (MEFs) and attempting to derive pluripotent ESCs. None of the 10 ESC lines derived from the 43 embryos were homozygous for the Oct4-knockout allele (Fig. 4b) , indicating loss of pluripotency in Oct4A-null embryos. Immunocytochemical analysis of the mutant outgrowths revealed many condensed and fragmented Cdx2 − nuclei along with Cdx2 + trophectoderm cells (Fig. 4a ). Interestingly, Nanog was still detectable in some Cdx2 − cells, but it was only localized to the cytoplasm, instead of the nucleus.
As expression of Nanog and Oct4-GFP was persistent in the Oct4A-null embryos between E2.5 and E4.5, we postulated that these defective embryos could be rescued by WT embryos for differentiation into certain types of somatic cell. Accordingly, we aggregated Rosa26 +/− Oct4A-null eight-cell embryos with WT embryos. After 24 h of culture, chimaeric embryos with homozygous (Oct4A-knockout) and heterozygous (control) mutants were separately transferred into pseudopregnant mice. E13.5-E14.5 fetuses were collected and subjected to β-galactosidase gene (LacZ ) staining (Fig. 4c ). Consistent with our in vitro study, Oct4A-null embryos contributed exclusively to the placental tissue of trophoblast origin, and not to the embryo proper (0/7 versus 10/11 in control). Furthermore, after aggregating with embryos of ICR mice, Oct4A-null embryos also did not contribute to the formation of adult mice, as shown by the coat colour, whereas four of five control embryos did (Fig. 4d) . These results demonstrated that Oct4A-depleted cells lost pluripotency and could only form extraembryonic tissues, supporting the importance of Oct4 as the gatekeeper of pluripotency 3 .
Studies have shown that the nuclei of terminally differentiated somatic cells can be reverted back to a totipotent state after nuclear transplantation into enucleated oocytes 40 . To explore whether maternal Oct4A is critical in the reprogramming of somatic cells using oocytes, NT experiments were conducted with the Oct4A-null oocytes from Oct4 flox/flox -Zp3 Cre/+ female mice. By using both immunocytochemistry ( Supplementary Fig. S4a ) and real-time RT-PCR ( Supplementary  Fig. S4b ), we observed that Oct4A-null oocytes still activated the expression of pluripotent genes (Oct4 and Nanog ) in the ICM and the trophectoderm marker gene (Cdx2) in the trophectoderm in all 28 cloned embryos analysed.
To further assess whether maternal Oct4A-null oocytes can induce pluripotency in somatic cells, we derived ESCs from NT embryos using these oocytes as recipient oocytes and CAG-mRFP (monomeric red fluorescent protein) and Oct4-GFP double transgenic male MEFs as donor cells. Of 135 reconstructed embryos, 78 developed to the morula stage and expressed both CAG-mRFP and Oct4-GFP on day 3 of culture (Fig. 5a ). These morulae were plated on irradiated MEFs (Fig. 5b) and gave rise to nine ESC lines ( Supplementary Fig. S4c ). Chromosome counts from metaphase spreads showed that seven of the nine NT-ESC lines were normal, with 40 chromosomes. Four of the seven NT-ESC lines-RG1, RG5, RG6 and RG8-were tested with the tetraploid complementation assay, the most stringent test for pluripotency ( Fig. 5c ). All ESC-tetraploid embryo aggregates developed to the Supplementary Fig. S5 .
blastocyst stage and had ESCs integrated into the ICM (Fig. 5d ). After being transferred into the uterus of pseudopregnant female mice, the RG5 ESC line did not support any of the 30 aggregates to full-term development. RG6 gave rise to two pups of 50 transferred (one dead; one alive, initiated breathing but died shortly thereafter). RG1 and RG8 ESC lines did very well with the test. On E19, we recovered 17 full-term male pups of 31 aggregates transferred (54.8%) in total from RG1 ( Supplementary Fig. S4e ) and 18 pups of 45 aggregates transferred (40%) in total from RG8. These offspring expressed CAG-mRFP ubiquitously in the body (Fig. 5e ) and Oct4-GFP specifically in the gonads (Fig. 5f ). Of these 17 pups from line RG1, 11 initiated breathing and were set up with foster mothers, and five survived to adulthood ( Fig. 5g ) and were fertile. Twelve of the 18 pups from RG8 initiated breathing but were rejected by their foster mothers. The pluripotency of RG6 and RG8 ESC lines was further confirmed by differentiation into cells of all three embryonic germ layers in the teratoma assay ( Supplementary Fig. S4d ). Our NT data unequivocally demonstrated that the reprogramming engine in oocytes could work effectively to reprogram somatic cells into cells of a pluripotent state without Oct4A.
In conclusion, our results demonstrated that Oct4A is not the master regulator responsible for initiating totipotency-pluripotency in natural reprogramming by maternal factors in oocytes. The maternal and zygotic Oct4A-null blastocysts maintained the ability to activate Nanog and Oct4-GFP expression, indicating that unknown pathways other than the Oct4-centred pluripotency-regulating network are active in embryos at both the totipotent and pluripotent stages of development and function upstream of Oct4A in driving pluripotency.
METHODS
Methods and any associated references are available in the online version of the paper. The Zp3 promoter-driven Cre expression supports the inactivation of maternally expressed genes in growing oocytes 41 as early as day 5 after birth 42 . DNA extraction and PCR genotyping were carried out as reported previously 12 . As shown in Supplementary Fig. S1a , the intact Oct4 allele and the loxP site were detected by primer pair B (forward, GOF-D1, reverse, GOF-R1; amplicon size: WT, 415 bp; floxed, 449 bp), and the Oct4 allele was found to be deleted by primer pair C (forward, GOF-AatII; reverse, GOF-ApaL1; amplicon size, 245 bp). A representative PCR genotyping result is shown in Supplementary Fig. S1c . Nested PCR was used to genotype individual oocytes and blastomeres as described 43 with combinations of the above primers: GOF-AatII, GOF-D1 and GOF-R1 as outer primers for the primary amplification, and GOF-AatII, GOF-D1 and GOF-ApaL1 as inner primers for the nested amplification. Three genotypes of Oct4 alleles were distinguished by amplicons of different sizes: WT (362 bp), floxed (396 bp) and deleted (245 bp). For genotyping cells with Oct4-GFP, another set of primers (outer, GOF-AatII, GOF-HindIII, and GOF-R1; inner, GOF-AatII, GOF-ApaL1 and Oct4R344: 5 -GAGAAGGCGAAGTCTGAAGC-3 ) with amplicons of different sizes, WT (345 bp), floxed (379 bp) and deleted (245 bp), were used.
A protocol for animal handling and maintenance for this study was approved by the Landesamt für Natur, Umwelt und Verbraucherschutz Nordrhein-Westfalen under the supervision of a certified veterinarian in charge of the Max Planck Institute animal facility.
Embryo collection, culture and immunocytochemistry. Embryos from various
matings were flushed out of the mouse oviducts or uteri in M2 medium as described by Hogan et al. 44 at 2.5, 3.5 or 4.5 days post coitum (dpc) to collect embryos at stages of development as required for specific experiments.
Whole-mount immunostaining was carried out as described 29 . Briefly, embryos were fixed in 4% paraformaldehyde (20 min), permeabilized with 0.1% Triton X-100 (Sigma-Aldrich) for 1 h and blocked with 3% bovine serum albumin in PBS for 1 h. This was followed with binding of primary antibodies (overnight at 4 • C) and secondary antibodies (Alexa 488-conjugated goat anti-rabbit IgG, Alexa 488-conjugated goat anti-mouse IgG, Alexa 488-conjugated donkey anti-goat IgG, Alexa 568-conjugated donkey anti-rabbit IgG and Alexa 647-conjugated donkey anti-mouse IgG (Invitrogen), Cy3-conjugated goat anti-rat IgG or Cy3-conjugated goat anti-mouse IgG (Jackson Laboratory) at a 1:400 dilution for 1 h. The following primary antibodies were used: rabbit anti-Nanog IgG (1:200; Cosmo Bio Company, REC-RCAB0002PF), mouse anti-Oct4 IgG (1:100; Santa Cruz Biotechnology, clone C-10, SC-5279), rabbit anti-Oct4 IgG (1:2,500; generated in our laboratory) 45 , goat anti-Oct4 IgG (1:100; Santa Cruz Biotechnology, SC-8628), mouse anti-Cdx2 (1:100; BioGenex, clone CDX2-88, MU392-UC) and rat anti-Troma-1 (1:100; DSHB). Some samples were counterstained with 5 µM DRAQ5 (Biostatus) for 30 min. Samples were examined under a laser scanning confocal microscope (UltraVIEW; PerkinElmer Life Sciences) with 488 nm, 568 nm and 647 nm lasers. Immunocytochemistry experiments were repeated two or three times with 30-100 embryos in each experiment.
RNA extraction, complementary DNA synthesis and real-time RT-PCR.
For real-time analysis of gene expression, embryos were harvested in RLT buffer (Qiagen) and processed as previously described 46 . Briefly, total RNA was extracted from individual blastocysts using a MicroRNeasy kit (Qiagen) and cDNA synthesis was carried out with a High Capacity cDNA Archive Kit (Applied Biosystems) according to the manufacturer's instructions.
Real-time PCR was carried out on the ABI PRISM 7900HT sequence detection system (Applied Biosystems) using TaqMan probes from Applied Biosystems. All primers used are listed in Supplementary Tables S3. Two to six biological replicates were used, and each sample was run with three technical replications; an RT blank and a no-template blank served as negative controls. The C T values were collected using Applied Biosystems SDS v2.0 software and transferred to a Microsoft Excel spreadsheet for further relative quantification analysis using the C T method (User Bulletin no. 2, ABI PRISM 7700 sequence detection system, 1997). Single oocyte real-time RT-PCR using the Biomark 48.48 Dynamic Array System (Fluidigm) was carried out as previously described 19 . All real-time RT-PCR source data can be found in Supplementary Informations.
Microinjection of siRNA into zygotes. Zygotes were collected in the morning after mating from superovulated or natural ovulated Oct4 flox/flox -Zp3 Cre/+ female mice. Microinjection of siRNA duplexes into zygotes was carried out using an Eppendorf FemtoJet microinjector and Narishige micromanipulators as previously described 29 . Approximately 2 pl of siRNAs (20 µM) was injected into cytoplasm of zygotes. Scrambled siRNA duplexes or siRNA duplexes against GFP were used as control. The injected zygotes were then cultured with KSOM AA (potassium simplex optimized medium plus 19 natural amino acids) 47 in a humidified 5% CO 2 in air at 37 • C. Expression of the target genes was analysed at the blastocyst stage (3.5 dpc) in pools of 10-20 embryos per sample. The target sequences of siRNA are listed in Supplementary Table S4 .
Somatic cell nuclear transfer. Seven-to 9-week-old Oct4 flox/flox (control oocytes) and Oct4 flox/flox -Zp3 Cre/+ (Oct4-null oocytes) female mice were used to collect oocytes and cumulus cells after superovulation. Superovulation and collection of oocytes and cumulus cells, nuclear transfer using ovarian cumulus cells, and activation of reconstructed oocytes were all carried out essentially as previously described 46, 48 . Six hours after the onset of activation, the constructs were washed carefully in a four-well dish (Nunc, 176749) with 0.5 ml of alpha minimal essential medium (Invitrogen, 12571-063) supplemented with 0.4% of bovine serum albumin (Sigma-Aldrich, A3311) without cytochalasin B under 5% CO 2 in air for 4 days. The blastocysts obtained were subjected to immunostaining, genotyping and real-time RT-PCR.
For derivation of ESCs from NT embryos, 8-to 12-week-old Oct4 /flox -Zp3 Cre/cre female mice were used to collect Oct4-null oocytes after superovulation. MEFs of passages 2-4, derived from male E13.5 embryos by crossing CAG-mRFP (ref. 49) male mice with Oct4-GFP female mice (GOF-18) (ref. 21) , were used as nucleus donors. The NT procedures were the same except that MEF cells were briefly exposed to HVJ-E Sendai virus extract (www.cosmobio.co.jp) and then placed into the perivitelline space of recipient Oct4-null-enucleated oocytes on the side opposite the first polar body 50 . The constructs were transferred into KSOM AA and cultured for 1-2 h in an incubator with 5% CO 2 in air at 37 • C to induce fusion before activation. The morulae obtained on day 3 of culture were subjected to the ESC derivation procedure according to a previous report 51 .
Western blotting. Western blot was carried out as described previously 52 . Briefly, 400 WT and 400 maternal Oct4A-null oocytes were collected in PBS. Oocytes, 10,000 ESCs as well as cumulus cells were lysed in RIPA buffer (50 mM Tris at pH 8.0, 300 mM NaCl, 1% IGEPAL CA-630, 0.5% sodium deoxycholate, 1 mM EDTA, 1 × protease inhibitors (Roche) and 1 × phosphatase inhibitors (Sigma-Aldrich)) containing 50 units of Benzonase (Merck) on ice for 1 h. The lysate was cleared by centrifugation and supernatants were collected. An amount of supernatant equivalent to 250 oocytes was resolved using gel electrophoresis. Primary antibody used for western blot was mouse monoclonal anti-Oct4 IgG (Santa Cruz Biotechnology, clone C-10, SC-5279). The western blot experiment was repeated twice.
Sequencing. Products of quantitative PCR were gel purified and ligated into PCR2.1-TOPO vector (Invitrogen) according to the manufacturer's instructions. For each sample, six colourless colonies were picked and sent to GATC Biotech AG (Konstanz) in 96-well format for sequencing using M13 reverse primer.
Generation and analysis of chimaeric embryos. To assess the pluripotency of
Oct4-inactivated embryos in vivo, we aggregated mutated eight-cell embryos (obtained from crossing Oct4 flox/flox -Zp3 Cre/+ -ROSA26 +/+ female mice with Oct4 +/ -ROSA26 +/+ male mice)-after removal of the zonae pellucidae by acidic Tyrode's solution (Sigma) and biopsy for genotyping by nested PCR-with eight-cell embryos from WT B6C3F1 mice for LacZ evaluation of chimaerism in the fetus or for coat colour evaluation in albino CFW mice. Following 24 h of culture in KSOM AA , successfully fused and genotyped chimaeric blastocysts carrying heterozygous (69 in total as control) and homozygous mutants (60 in total as Oct4 knockout) were transferred separately into the uteri of 10 ICR pseudopregnant recipients. Eleven fetuses carrying heterozygous mutants and seven fetuses carrying homozygous mutants were recovered on E13.5 from eight recipients and subjected to whole-mount LacZ staining as previously described 53 . Five full-term pups from each of the controls and the knockout mutants were obtained from two recipients for evaluation of coat colour chimaerism.
Derivation of ESC lines. E2.5 embryos were cultured on MEFs to establish ESC lines with a standard procedure 48 after removal of the zonae pellucidae (as described above). All ESCs lines were newly derived in the present study and tested negative for mycoplasma contamination. The complete ESC medium composition was as follows: 4 mM l-glutamine, 100 units ml −1 penicillin, 100 µg ml −1 streptomycin, DOI: 10.1038/ncb2816 M E T H O D S 0.1 mM β-mercaptoethanol, 0.1 mM non-essential amino acids, 1,000 units ml −1 LIF (Chemicon) and 15% fetal bovine serum (Invitrogen, 10165-185) in DMEM (Gibco, 31885-023).
Tetraploid embryo complementation assay for NT-ESCs. The assay was conducted as described previously 54 . Briefly, two-cell embryos were flushed 20 h post-hCG (human chorionic gonadotrophin) from the oviducts of B6C3F1 mice and fused with a peak pulse of 50 V for 35 µs in 0.3 M mannitol to make tetraploid embryos. The tetraploid embryos were cultured overnight in KSOM AA . Then clumps of 15-20 trypsin-treated ESCs were transferred into individual depressions in drops of KSOM AA under mineral oil. Meanwhile, batches of 30-50 embryos were briefly incubated in acidified Tyrode's solution 44 to remove the zona pellucida. Two embryos were placed on each ESC clump and cultured in an incubator with 5% CO 2 in air at 37 • C. After 24 h of culture, 10-12 embryos at blastocyst stage were transferred into one uterine horn of a 2.5 dpc pseudopregnant recipient for full term development. Fig. 5 and source data for e are shown in Supplementary  Table 5 .
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